Methods For Treating Inflammatory Conditions
AssigneeMelior Discovery, Inc.
InventorsAndrew Reaume, Heather Hain, Michael S. Saporito
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising tenilsetam or pharmaceutically acceptable salts thereof that are useful in modulating inflammation. In particular, the compounds or pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder involving inflammation, including, but not limited to, delayed type hypersensitivity and contact hypersensitivity.
Claims26
1-25. (canceled)
A method of treating delayed-type hypersensitivity, contact dermatitis, atopic dermatitis, or septic shock in a human comprising administering to the human in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I
- and pharmaceutically acceptable carrier, wherein:
- X is 2-thienyl, 3-thienyl, 2-furyl, 3-furyl, or phenyl, each unsubstituted, mono-substituted, di-substituted, or tri-substituted with, independently, OH, halogen, C1-C4 alkyl, C1-C4 alkoxy, or (C1-C4) alkoxy-(C1-C4) alkyl;
- R1 and R4 are, independently, H or C1-C4 alkyl;
- R2a and R2b are, independently, H, OH, or C1-C4 alkyl, or, together, R2a and R2b are C═O;
- R3a and R3b are, independently, H, OH, or C1-C4 alkyl, or, together, R3a and R3b are C═O;
- and
- RX is H, C1-C4 alkyl, C1-C4 alkoxy, or (C1-C4) alkoxy-(C1-C4) alkyl;
- or a pharmaceutically acceptable salt thereof, wherein the compound of formula I is administered in the absence of another therapeutic agent.
A method of treating pruritis in a human comprising administering to the human in need thereof a therapeutically effective amount of a compound of formula I
- wherein:
- X is 2-thienyl, 3-thienyl, 2-furyl, 3-furyl, or phenyl, each unsubstituted, mono-substituted, di-substituted, or tri-substituted with, independently, OH, halogen, C1-C4 alkyl, C1-C4 alkoxy, or (C1-C4) alkoxy-(C1-C4) alkyl;
- R1 and R4 are, independently, H or C1-C4 alkyl;
- R2a and R2b are, independently, H, OH, or C1-C4 alkyl, or, together, R2a and R2b are C═O;
- R3a and R3b are, independently, H, OH, or C1-C4 alkyl, or, together, R3a and R3b are C═O;
- and
- RX is H, C1-C4 alkyl, C1-C4 alkoxy, or (C1-C4) alkoxy-(C1-C4) alkyl;
- or a pharmaceutically acceptable salt thereof, wherein the compound of formula I is administered in the absence of another therapeutic agent.
A method of treating delayed-type hypersensitivity, contact dermatitis, atopic dermatitis, or septic shock in a human comprising administering to the human in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I
- and pharmaceutically acceptable carrier, wherein:
- X is 2-thienyl, 3-thienyl, 2-furyl, 3-furyl, or phenyl, each unsubstituted, mono-substituted, di-substituted, or tri-substituted with, independently, OH, halogen, C1-C4 alkyl, C1-C4 alkoxy, or (C1-C4) alkoxy-(C1-C4) alkyl;
- R1 and R4 are, independently, H or C1-C4 alkyl;
- R2a and R2b are, independently, H, OH, or C1-C4 alkyl, or, together, R2a and R2b are C═O;
- R3a and R3b are, independently, H, OH, or C1-C4 alkyl, or, together, R3a and R3b are C═O;
- and
- RX is H, C1-C4 alkyl, C1-C4 alkoxy, or (C1-C4) alkoxy-(C1-C4) alkyl;
- or a pharmaceutically acceptable salt thereof;
- wherein the pharmaceutical composition comprises a solvent;
- and
- wherein the pharmaceutical composition is free of a free radical scavenger.
Dependencies are inferred from the claim text.